查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005150

抗血管內皮生長因子（抗 VEGF）療法市場：2026-2032 年全球市場預測，依產品類型、治療領域、給藥途徑、通路和最終用戶分類。

Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年抗血管內皮生長因子（抗 VEGF）療法市值為 98.7 億美元，預計到 2026 年將成長至 108.5 億美元，複合年成長率為 9.58%，到 2032 年將達到 187.3 億美元。

主要市場統計數據
基準年 2025 98.7億美元
預計年份：2026年 108.5億美元
預測年份 2032 187.3億美元
複合年成長率 (%) 9.58%

簡單概述抗 VEGF 療法的發展歷程以及影響現代視網膜治療的相關臨床和商業性因素。

抗血管內皮生長因子（VEGF）療法徹底改變了視網膜疾病的臨床治療，從實驗性生物製藥發展成為治療威脅視力疾病的標準療法。這些藥物針對血管內皮生長因子（VEGF）通路，透過抑制病理性新生血管形成和血管滲漏，穩定或改善許多患者的視力。隨著時間的推移，治療模式已從不頻繁但負擔沉重的干涉措施轉變為以患者為中心的治療方法，兼顧療效、安全性和給藥便利性。

臨床重點、技術進步和商業性壓力如何交織，重新定義視網膜治療的產品價值和醫療保健服務。

抗VEGF藥物領域正經歷著變革性的轉變，這主要由臨床、技術和商業性因素共同驅動。在臨床方面，人們越來越關注如何在不影響長期視力預後的前提下減輕治療負擔，這促使人們對能夠延長給藥間隔的藥物和劑型產生了濃厚的興趣。在技​​術方面，製劑、分子設計和給藥裝置的漸進式創新正在帶來以穩定性、無菌性和給藥效率為核心的全新提案主張。

美國近期關稅調整對生物眼科治療藥物供應鏈韌性、籌資策略和分銷計劃的影響。

美國近期關稅政策的變化和貿易政策調整，進一步加劇了包括抗VEGF製劑在內的生物製藥全球供應鏈規劃和成本結構的波動。這些政策轉變正在影響策略採購決策，促使相關人員重新評估製造地、區域供應冗餘和供應商多元化，以減輕進口相關成本波動的影響。為此，製造商和經銷商正在探索國內包裝、本地填充和加工夥伴關係以及替代物流方案，以維持供應的連續性並保護利潤率。

將產品屬性、適應症、劑型、通路和醫療保健環境與策略採用因素連結起來的綜合細分分析。

細分市場層面的趨勢揭示了不同產品、適應症、給藥途徑、通路和終端用戶環境所帶來的微妙價值路徑差異。產品類型（例如阿柏西普、Bevacizumab、布羅盧西珠單抗和雷珠單抗）的差異會影響臨床定位、安全性討論和採購行為。每種分子的臨床特徵指南著治療流程和支付方的優先排序。治療領域的細分（例如老齡化黃斑部病變、糖尿病黃斑部水腫、近視性脈絡膜新生血管和視網膜靜脈阻塞）明確了患者群體、轉診途徑和預期治療頻率，從而影響醫療服務提供者在權衡療效和臨床資源時如何選擇藥物。

影響招聘和籌資策略的區域趨勢和准入考慮因素，包括美洲、歐洲、中東和非洲以及亞太地區。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢受不同的管理體制、醫療基礎設施和支付方環境的影響。在美洲，與支付方的大量談判和垂直整合的醫療服務體系影響著處方藥清單和合約策略，而大規模三級醫療機構和門診手術網路則決定著治療能力和病患處理能力。同時，生物相似藥和仿單標示外用藥相關法規的澄清可能會改變競爭動態和採購慣例。

成熟製藥公司、生技創新者和服務供應商之間的競爭與合作動態會影響產品差異化和市場成功。

該領域的競爭動態由大型跨國製藥公司、眼科專家和生物技術創新者共同塑造，他們都在追求差異化的分子設計和遞送平台。傳統分子藥物憑藉豐富的臨床經驗和醫療服務提供者的認可，在臨床實踐中保持著穩固的地位；而新參與企業圖透過持久療效、更高的安全性或醫療設備帶來的便利性來實現差異化。同時，生物相似藥和替代生物製藥的研發也在加速推進，迫使現有企業加強對產品生命週期策略的投入，強化服務模式，並累積證據以鞏固其臨床地位。

為了實現永續推廣，製造商和醫療保健提供者必須解決在協調臨床證據、劑型、供應彈性和支付方參與方面面臨的實際策略挑戰。

產業領導企業應優先考慮整合臨床差異化、營運效率和支付方參與的整合策略。首先，他們需要投資於證據的積累，以預測支付方可能提出的問題，並透過將隨機數據與以安全性、治療永續性和以患者為中心的療效為重點的可操作的真實世界研究相結合，加強價值對話。其次，他們需要最佳化產品交付方式，使注射器和管瓶劑型與醫療服務提供者的工作流程相匹配，從而縮短給藥時間、減少廢棄物、簡化庫存管理並減少臨床實踐中的摩擦。

嚴謹且多方面的研究途徑，結合文獻整合、相關人員訪談、細分映射和情境檢驗，確保獲得可操作的見解。

本分析的調查方法結合了多方面證據的整合和結構化的專家檢驗，以確保其嚴謹性和相關性。此方法首先對同行評審的臨床文獻、監管申報文件、安全資訊以及最新的公共進展進行全面審查，為治療方案、安全考量和法規環境奠定基礎。其次，研究人員與包括視網膜專家、藥屋主任、醫院採購經理、契約製造和分銷合作夥伴在內的眾多相關人員進行了定性訪談，以了解實際情況和戰略重點。

策略挑戰的整合強調產品創新、營運可行性、證據產生以及協作存取模式整合的必要性。

整體而言，抗VEGF療法領域正處於策略轉折點，隨著臨床預期、給藥創新和商業性現實的交匯，醫療服務模式正在重塑。持續的競爭優勢將源自於將分子和器械層面的差異化與便利的操作、可靠的實證醫學計畫以及穩健的供應鏈相結合的能力。醫療服務提供者和保險公司越來越重視已證實的患者獲益與治療營運成本之間的平衡，這進一步凸顯了給藥便利性、安全性以及可靠供應的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗血管內皮生長因子（抗VEGF）療法市場：依產品類型分類

  • 阿柏西普
  • Bevacizumab
  • 布羅盧西珠單抗
  • 雷尼珠單抗

第9章：抗血管內皮生長因子（抗VEGF）治療藥物市場：依治療領域分類

  • 老齡化黃斑部病變
  • 糖尿病黃斑部水腫
  • 近視性脈絡膜新生血管
  • 視網膜靜脈阻塞

第10章：抗血管內皮生長因子（抗VEGF）治療藥物市場：依給藥途徑分類

  • 玻璃體內注射
    • 預填充式注射器
      • 預填充多劑量
      • 單劑量預填充
    • 管瓶
      • 多管瓶小瓶
      • 單劑量管瓶
  • 結膜下注射

第11章：抗血管內皮生長因子（抗VEGF）治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 抗血管內皮生長因子（抗VEGF）療法市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 眼科診所
  • 專科診所

第13章 抗血管內皮生長因子（抗VEGF）治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗血管內皮生長因子（抗VEGF）治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗血管內皮生長因子（抗VEGF）治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗血管內皮生長因子（抗VEGF）治療市場

第17章：中國抗血管內皮生長因子（抗VEGF）療法市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alteogen
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion
  • Coherus BioSciences Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals
  • Johnson & Johnson Private Limited
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Ocumension Therapeutics
  • Outlook Therapeutics
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Bioepis Co. Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xbrane Biopharma AB
Product Code: MRR-B168537775F5

The Anti-vascular Endothelial Growth Factor Therapeutics Market was valued at USD 9.87 billion in 2025 and is projected to grow to USD 10.85 billion in 2026, with a CAGR of 9.58%, reaching USD 18.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.87 billion
Estimated Year [2026] USD 10.85 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.58%

Concise orientation to the evolution of anti-VEGF therapeutics and the interconnected clinical and commercial forces shaping contemporary retinal care

Anti-VEGF therapeutics have transformed the clinical management of retinal diseases, evolving from experimental biologics into foundational standards of care for conditions that threaten vision. These agents target vascular endothelial growth factor pathways to reduce pathological neovascularization and vascular leakage, thereby stabilizing or improving visual acuity for many patients. Over time, treatment paradigms have shifted from infrequent, high-burden interventions toward more patient-centric regimens that balance efficacy, safety, and dosing convenience.

Current clinical practice emphasizes personalized treatment strategies that consider lesion characteristics, disease chronicity, patient comorbidities, and adherence constraints. Advances in drug formulation and delivery platforms have introduced variations in presentation and administration that materially affect clinic workflows and procurement decisions. Concurrently, heightened scrutiny around safety signals, comparative outcomes, and value-based reimbursement is prompting manufacturers and providers to adopt more transparent evidence generation and risk-mitigation approaches.

This introduction frames the subsequent analysis by focusing on how product attributes, therapeutic indications, administration routes, distribution systems, and end-user dynamics interact to shape commercial and clinical outcomes. It also sets expectations for strategic priorities, including differentiation through dosing frequency, device format innovation, real-world evidence generation, and collaborative models between manufacturers and care providers to improve patient access and treatment continuity.

How converging clinical priorities, technological advances, and commercial pressures are redefining product value and care delivery in retinal therapeutics

The anti-VEGF landscape is undergoing transformative shifts driven by a convergence of clinical, technological, and commercial forces. Clinically, there is an intensified focus on reducing treatment burden without compromising long-term visual outcomes, which is propelling interest in agents and delivery formats that permit extended dosing intervals. Technologically, incremental innovations in formulation, molecular design, and delivery devices are enabling new value propositions centered on stability, sterility, and administration efficiency.

Commercially, payers and health systems increasingly demand robust comparative effectiveness and real-world safety data, prompting manufacturers to invest in longitudinal registries and pragmatic studies. Regulatory pathways are also evolving to address biosimilar entrants and alternative therapeutic modalities, which increases competitive pressure and encourages strategic alliances and licensing deals. In parallel, provider networks are optimizing care delivery through ambulatory surgical centers, integrated ophthalmic clinics, and specialty pharmacies that can streamline patient pathways and inventory management.

Together, these shifts are reshaping how stakeholders prioritize product attributes, contract structures, and collaboration models. Manufacturers that align molecule properties with clinician workflows, invest in post-approval evidence generation, and design flexible commercial channels will be better positioned to capture clinical momentum and sustain adoption amid intensifying competition.

Implications of recent United States tariff adjustments on supply chain resilience, sourcing strategies, and distribution planning for biologic ocular therapies

Recent tariff developments and trade policy adjustments in the United States have introduced additional variables into global supply chain planning and cost structures for biologic therapies, including anti-VEGF agents. These policy shifts have influenced strategic sourcing decisions, encouraging stakeholders to re-evaluate manufacturing footprints, regional supply redundancy, and supplier diversification to mitigate exposure to import-related cost fluctuations. Manufacturers and distributors have responded by considering onshore packaging, local fill-finish partnerships, and alternative logistics arrangements to preserve supply continuity and protect margin integrity.

For providers and pharmacies, the indirect effects of tariff-related adjustments appear in procurement negotiations, inventory strategies, and contracting terms. Procurement teams are strengthening vendor agreements to include clauses that address unexpected tariff fluctuations and are increasing collaboration with specialty distributors to align delivery schedules with clinical demand. Meanwhile, contract manufacturers and component suppliers have accelerated dialogue around qualification of secondary sources for vials, syringes, and single-use devices to reduce bottlenecks that can be exacerbated by import constraints.

Overall, these trade policy dynamics underscore the importance of supply chain resilience planning as an operational imperative. Stakeholders who proactively map their supplier ecosystems, stress-test distribution contingencies, and embed tariff sensitivity into pricing and contracting models will be better prepared to maintain access and operational stability in an uncertain trade environment.

Integrated segmentation analysis linking product attributes, indications, administration formats, distribution pathways, and care settings to strategic adoption levers

Segment-level dynamics reveal nuanced pathways to value that differ by product, indication, administration route, distribution channel, and end-user setting. Product type distinctions among aflibercept, bevacizumab, brolucizumab, and ranibizumab drive clinical positioning, safety conversations, and procurement behavior; each molecule's clinical profile informs where it will be prioritized within treatment algorithms and by payers. Therapeutic area segmentation across age related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, and retinal vein occlusion clarifies patient populations, referral pathways, and expected treatment cadence, influencing how providers select agents to balance efficacy and clinic capacity.

Route-of-administration choices shape device and workflow requirements; intravitreal injection remains the primary delivery mechanism with practical sub-segmentation into prefilled syringe and vial formats. Prefilled syringe options further divide into multi-dose prefilled and single dose prefilled presentations, while vial presentations split into multi-dose vial and single dose vial formats, each combination carrying distinct sterility, handling, and inventory implications. Subconjunctival injection represents a smaller but strategically important alternative that may be relevant for specific delivery innovations or clinical scenarios. Distribution channel distinctions among hospital pharmacies, online pharmacies, and retail pharmacies affect stocking strategies, delivery lead times, and reimbursement interactions. End-user segmentation encompassing ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics highlights variation in administration capacity, staffing competencies, and purchasing arrangements, which in turn informs targeted commercial engagement approaches.

Taken together, these segmentation layers create a multidimensional decision matrix for manufacturers and providers. Effective strategies will integrate product-level differentiation with tailored distribution models and end-user support programs to optimize adoption across clinical settings while addressing operational constraints related to dosing format and administration logistics.

Regional dynamics and access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption and procurement strategies

Regional dynamics are shaped by distinct regulatory regimes, care delivery infrastructures, and payer environments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidated payer negotiations and vertically integrated provider systems influence formulary placement and contracting strategies, while large tertiary centers and ambulatory surgical networks shape treatment capacity and patient throughput. Meanwhile, regulatory clarity around biosimilars and off-label use can alter competitive dynamics and procurement practices.

In Europe, Middle East & Africa, reimbursement heterogeneity and regional procurement mechanisms create differentiated pathways to market access; national health technology assessment processes and centralized tendering in some countries emphasize cost-effectiveness and comparative evidence. Provider density and the distribution of specialty clinics versus hospital-based ophthalmology services further modulate treatment accessibility. The Asia-Pacific region presents diverse market archetypes ranging from well-equipped urban centers to under-resourced rural settings, with rapid adoption in high-volume urban clinics and an increasing focus on scalable care models and local manufacturing partnerships to improve access.

Across all regions, supply chain robustness, regulatory harmonization efforts, and local clinician practice patterns will determine the pace and shape of therapeutic uptake. Stakeholders must therefore adopt regionally nuanced engagement plans that align clinical value propositions with reimbursement pathways and infrastructure realities to effectively expand access and sustain long-term adoption.

Competitive and collaborative dynamics among legacy manufacturers, biotech innovators, and service providers that define product differentiation and go-to-market success

Competitive dynamics in the space are driven by a mix of large multinational pharmaceutical companies, specialized ophthalmology companies, and biotech innovators pursuing differentiated molecular designs and delivery platforms. Legacy molecules retain a strong clinical foothold due to extensive real-world experience and established provider familiarity, while newer entrants attempt to differentiate through extended-duration efficacy, improved safety profiles, or device-enabled convenience. Concurrently, development of biosimilar and alternative biologic constructs has intensified, prompting established players to invest in lifecycle strategies, enhanced service models, and evidence generation to defend clinical position.

Partnerships and strategic alliances are increasingly common as companies seek to combine clinical development strengths with commercial reach and manufacturing capacity. Contract manufacturing organizations and specialized fill-finish partners are critical nodes in the supply chain, especially for complex biologics where sterility and cold chain integrity determine product viability. Additionally, collaboration with specialty distributors and pharmacy partners supports more efficient deployment into ambulatory surgical centers and specialty clinics, where most intravitreal administrations occur.

Investor attention and R&D investment continue to flow into formulation improvements, device innovation, and combination approaches that could alter the therapeutic calculus. Companies that align product innovation with pragmatic commercialization models, robust safety monitoring, and clinician engagement will hold an advantage in a market where clinical differentiation must be coupled with operational feasibility to achieve sustained uptake.

Practical strategic imperatives for manufacturers and providers to align clinical evidence, formats, supply resilience, and payer engagement for sustained adoption

Industry leaders should prioritize integrated strategies that align clinical differentiation with operational execution and payer engagement. First, invest in evidence generation that anticipates payer questions by combining randomized data with pragmatic real-world studies focused on safety profiles, treatment durability, and patient-centered outcomes to strengthen value conversations. Second, optimize product presentation choices by aligning syringe and vial formats with provider workflows to reduce administration time, minimize wastage, and simplify inventory management, thereby lowering friction at the point of care.

Third, build supply chain resilience through diversified sourcing, regional manufacturing partnerships, and contingency plans that account for regulatory and trade policy variability. Fourth, develop targeted distribution and contracting strategies tailored to ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics, recognizing that each end-user type has unique procurement cycles and clinical staffing patterns. Fifth, engage early with payers and health system formulary committees to position therapeutic value within clinical pathways and to explore outcomes-based contracting or risk-sharing arrangements where appropriate. Finally, foster collaborative clinical education programs that support safe administration practices and adherence, and leverage digital tools to improve scheduling, patient reminders, and longitudinal outcomes tracking to enhance persistence and clinic efficiency.

Rigorous, multi-source research approach combining literature synthesis, stakeholder interviews, segmentation mapping, and scenario validation to ensure actionable insights

The research methodology underpinning this analysis combined multi-source evidence synthesis with structured expert validation to ensure rigor and relevance. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory filings, safety communications, and public policy updates to establish a factual base for therapeutic profiles, safety considerations, and regulatory context. Next, qualitative interviews were conducted with a cross-section of stakeholders including retinal specialists, pharmacy directors, hospital procurement leaders, contract manufacturers, and distribution partners to surface operational realities and strategic priorities.

Data triangulation techniques were applied to reconcile divergent inputs and to contextualize claims made in isolated sources. Segmentation mapping was used to align product attributes with therapeutic indications, administration formats, distribution channels, and end-user capabilities, facilitating a multi-dimensional view of adoption drivers. Supply chain and trade policy implications were assessed through scenario analysis to identify vulnerabilities and mitigation levers. Finally, findings were synthesized into actionable recommendations and validated through follow-up consultations with clinical and commercial experts to ensure the practical applicability of the insights presented.

Synthesis of strategic imperatives emphasizing the need to integrate product innovation, operational feasibility, evidence generation, and collaborative access models

In aggregate, the anti-VEGF therapeutic area is at a strategic inflection point where clinical expectations, delivery innovations, and commercial realities converge to reshape care delivery. Sustained competitive advantage will derive from the ability to marry molecular and device-level differentiation with operational simplicity, robust evidence programs, and resilient supply chains. Providers and payers will increasingly demand alignment between demonstrated patient benefit and the operational cost of delivering therapy, which elevates the importance of dosing convenience, safety clarity, and reliable availability.

As stakeholders navigate this environment, collaboration across manufacturers, providers, distributors, and payers will become more central to improving access and optimizing outcomes. Successful strategies will balance near-term operational improvements, such as format alignment and workflow integration, with longer-term investments in evidence generation and partnership models that share risk and reward. Ultimately, the capacity to translate scientific promise into consistent real-world benefit will determine which organizations lead the next phase of retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Product Type

  • 8.1. Aflibercept
  • 8.2. Bevacizumab
  • 8.3. Brolucizumab
  • 8.4. Ranibizumab

9. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Area

  • 9.1. Age Related Macular Degeneration
  • 9.2. Diabetic Macular Edema
  • 9.3. Myopic Choroidal Neovascularization
  • 9.4. Retinal Vein Occlusion

10. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route Of Administration

  • 10.1. Intravitreal Injection
    • 10.1.1. Prefilled Syringe
      • 10.1.1.1. Multi Dose Prefilled
      • 10.1.1.2. Single Dose Prefilled
    • 10.1.2. Vial
      • 10.1.2.1. Multi Dose Vial
      • 10.1.2.2. Single Dose Vial
  • 10.2. Subconjunctival Injection

11. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Anti-vascular Endothelial Growth Factor Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Ophthalmic Clinics
  • 12.4. Specialty Clinics

13. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-vascular Endothelial Growth Factor Therapeutics Market

17. China Anti-vascular Endothelial Growth Factor Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alteogen
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca Plc.
  • 18.8. Bausch Health Companies Inc.
  • 18.9. Bayer AG
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Celltrion
  • 18.13. Coherus BioSciences Inc.
  • 18.14. Eli Lilly and Company
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Intas Pharmaceuticals
  • 18.17. Johnson & Johnson Private Limited
  • 18.18. Kyowa Kirin Co. Ltd.
  • 18.19. Merck & Co. Inc.
  • 18.20. Novartis AG
  • 18.21. Ocumension Therapeutics
  • 18.22. Outlook Therapeutics
  • 18.23. Pfizer Inc.
  • 18.24. Regeneron Pharmaceuticals Inc.
  • 18.25. Samsung Bioepis Co. Ltd.
  • 18.26. Sanofi S.A.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Viatris Inc.
  • 18.29. Xbrane Biopharma AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)